We’re excited to announce the launch of our new CTSB-specific HCP ELISA Kit, designed to deliver highly sensitive and reliable detection of Cathepsin B (CTSB), one of the most critical high-risk host cell proteins in CHO-based biomanufacturing.
CTSB’s strong proteolytic activity can negatively impact product stability, quality, and safety. Yet generic HCP assays often miss CTSB due to insufficient sensitivity. Our new ELISA kit addresses this challenge with precise, high-specificity CTSB monitoring to strengthen process understanding and risk assessment.
Key Features
- Ultra-sensitive performance (LOD ~0.039 ng/mL)
- Broad dynamic range (0.3125–20 ng/mL)
- ICH Q2-compliance (CVs <10%)
- Fast results within hours
- Minimal cross-reactivity for clean, dependable data
Built with high-quality polyclonal antibodies, the CHO CTSB ELISA Kit integrates easily into existing QC workflows and works with both in-process samples and final drug substances, requiring only a standard ELISA plate reader.
This new kit reinforces BioGenes’ commitment to delivering specialized HCP detection tools that meet rising regulatory expectations and evolving bioprocessing challenges. As one of the few providers offering targeted assays for high-risk HCPs, BioGenes empowers manufacturers with greater clarity, confidence, and control.